MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
|11/25/14||MannKind Corporation to Present at The 26th Annual Piper Jaffray Healthcare Conference|
|VALENCIA, Calif., Nov. 25, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 PM (ET) at the New York Palace Hotel in New York City.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's webs... |
|11/03/14||MannKind Corporation Reports 2014 Third Quarter Financial Results|
|- Conference Call to Begin Today at 5:00 PM ET -
VALENCIA, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the third quarter ended September 30, 2014.
For the third quarter of 2014, total operating expenses were $38.3 million, compared to $44.8 million for the third quarter of 2013, a decrease of $6.5 million. Research and development (R&D) expenses decreased $8.1 million from $27.3 million for the third quarter of 2013 to... |
|10/27/14||MannKind Corporation to Hold 2014 Third Quarter Financial Results Conference Call on November 3, 2014|
|VALENCIA, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 third quarter financial results on Monday, November 3, 2014 and its management will host a conference call to discuss the third quarter financial results and other Company developments at 5:00 PM (Eastern Time) on November 3, 2014.
Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and Chief Operating Officer, Hakan Edstrom, and Corporate... |
|09/29/14||MannKind Announces Receipt of $150 Million Licensing Upfront Payment|
|VALENCIA, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it had received a $150 million upfront payment in connection with an exclusive worldwide collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) focuses on... |